Arama

EISSN 2148-4279

EJR IS INDEXED IN WEB OF SCIENCE AND PUBMED CENTRAL

European Journal of Rheumatology

PDF

HIGHLY CITED ARTICLES

Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus

Sawalha, Amr H.; Manzi, Susan.

Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg

Crayne, Courtney; Cron, Randy Q.

The emerging role of lung ultrasound in COVID-19 pneumonia

Lepri, Gemma; Orlandi, Martina; Lazzeri, Chiara; Bruni, Cosimo; Hughes, Michael; Bonizzoli, Manuela; Wang, Yukai; Peris, Adriano; Matucci-Cerinic, Marco.

Baricitinib in therapy of COPA syndrome in a 15-year-old girl

Krutzke, Sophia; Rietschel, Christoph; Horneff, Gerd.

New perspectives in the imaging of Raynaud's phenomenon

Herrick, Ariane L.; Dinsdale, Graham; Murray, Andrea.

The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis

Rosa, Irene; Romano, Eloisa; Fioretto, Bianca Saveria; Manetti, Mirko.

Pediatric Behcet's disease - clinical aspects and current concepts

Yildiz, Mehmet; Koker, Oya; Adrovic, Amra; Sahin, Sezgin; Barut, Kenan; Kasapcopur, Ozgur.

Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation

Miossec, Pierre.

The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia

Cai, Ken; He, Jianna; Wong, Peter K. K.; Manolios, Nicholas.

Characteristics of coexisting localized scleroderma and inflammatory arthritis

Reiff, Daniel; Crayne, Courtney B.; Mannion, Melissa L.; Cron, Randy Q.

All Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 6 results

Ranking

Release Date Sort Sort Article Type

Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: a case report

Nessrine Akasbi, Muhammad S Soyfoo

(Eur J Rheumatol 2015; 2: 35-36) DOI: 10.5152/eurjrheumatol.2014.14053

Abstract Full Text (PDF) Related Articles

Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

Sedat Yılmaz, Emre Tekgöz, Muhammet Çınar

(Eur J Rheumatol 2018; 5: 278-280) DOI: 10.5152/eurjrheum.2018.17183

Abstract Full Text (PDF) Related Articles

Use of non-TNF biologics for the treatment of neuro-Behçet’s disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab

Yusuf Karabulut

(Eur J Rheumatol 2021; 8: 223-227) DOI: 10.5152/eurjrheum.2021.20160

Abstract Full Text (PDF) Related Articles

Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: a case report

Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

Use of non-TNF biologics for the treatment of neuro-Behçet’s disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab

Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study

What are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome?

Severe Infections in Patients Treated with Tocilizumab for Systemic Diseases Other Than Rheumatoid Arthritis: A Retrospective Multicenter Observational Study